OCA
VRDN icon

OpenArc Corporate Advisory’s Viridian Therapeutics VRDN Stock Holding History

OpenArc Corporate Advisory’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$184K Hold
10,038
– – ﹤0.01% 764
2026
Q1 		$196K Hold
10,038
– – ﹤0.01% 688
2025
Q4 		$312K Buy
+10,038
New +$275K 0.01% 506

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

OpenArc Corporate Advisory's VRDN Position: Q2 2026 in Review

OpenArc Corporate Advisory held its Viridian Therapeutics (VRDN) position steady in Q2 2026 at 10,038 shares worth $184K. The position accounts for ﹤0.01% of the portfolio, ranked #764.

OpenArc Corporate Advisory first reported a position in VRDN in Q4 2025 and has held it in 3 quarters since. The position peaked at $312K in Q4 2025. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • OpenArc Corporate Advisory held 10,038 shares of Viridian Therapeutics worth $184K as of Q2 2026.
  • OpenArc Corporate Advisory left its Viridian Therapeutics share count unchanged in Q2 2026.
  • Viridian Therapeutics made up ﹤0.01% of OpenArc Corporate Advisory's portfolio in Q2 2026, its #764 holding.
  • OpenArc Corporate Advisory first reported a position in Viridian Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • OpenArc Corporate Advisory's Viridian Therapeutics position peaked at $312K in Q4 2025.
  • 214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on OpenArc Corporate Advisory's 13F filing for Q2 2026, filed 5 Aug 2026.